14.	Stockholders’ Equity

The Company has reserved for future issuance the following number of shares of common stock:

	June 30, 2018		December 31, 2017
Unvested restricted stock		956,247		1,164,040
Common stock options		385,974		666,717
Shares available for issuance under the 2013 Stock Option and Incentive Plan		4,618,038		3,273,334
Shares available for issuance under the 2013 Employee Stock Purchase Plan		788,503		788,503
		6,748,762		5,892,594

2010 and 2013 Stock Incentive Plans

In 2010, the Company adopted the Foundation Medicine, Inc. 2010 Stock Incentive Plan (the “2010 Stock Plan”) under which it granted restricted stock, incentive stock options (“ISOs”) and non-statutory stock options to eligible employees, officers, directors and consultants to purchase up to 1,162,500 shares of common stock. In the year ended December 31, 2013, the Company amended the 2010 Stock Plan to increase the number of shares of common stock available for issuance to 4,232,500.

In 2013, in conjunction with its initial public offering, the Company adopted the Foundation Medicine, Inc. 2013 Stock Option and Incentive Plan (the “2013 Stock Plan”) under which it may grant restricted and unrestricted stock, restricted stock units, ISOs, non-statutory stock options, stock appreciation rights, cash-based awards, performance share awards and dividend equivalent rights to eligible employees, officers, directors and consultants to purchase up to 1,355,171 shares of common stock. In connection with the establishment of the 2013 Stock Plan, the Company terminated the 2010 Stock Plan and the 512,568 shares which remained available for grant under the 2010 Stock Plan were included in the number of shares authorized under the 2013 Stock Plan. Shares forfeited or repurchased from the 2010 Stock Plan are returned to the 2013 Stock Plan for future issuance. On January 1, 2018 and 2017, the number of shares reserved and available for issuance under the 2013 Stock Plan increased by 1,461,671 and 1,403,616 shares of common stock, respectively, pursuant to a provision in the 2013 Stock Plan that provides that the number of shares reserved and available for issuance will automatically increase each January 1, beginning on January 1, 2014, by 4% of the number of shares of common stock issued and outstanding on the immediately preceding December 31 or such lesser number as determined by the compensation committee of the Board.

The terms of stock award agreements, including vesting requirements, are determined by the Board, or permissible designee thereof, subject to the provisions of the 2010 Stock Plan and the 2013 Stock Plan. Options, restricted stock, and restricted stock units granted by the Company typically vest over a four-year period. The options are exercisable from the date of grant for a period of 10 years. The exercise price for stock options granted is equal to the closing price of the Company’s common stock on the applicable date of grant.

Restricted Stock

For restricted stock, including restricted stock units, granted to employees, the intrinsic value on the date of grant is recognized as stock-based compensation expense ratably over the period in which the restrictions lapse. For restricted stock granted to non-employees, the intrinsic value is remeasured at each vesting date and at the end of the reporting period. The following table shows a roll forward of restricted stock activity pursuant to the 2010 Stock Plan and the 2013 Stock Plan:

	Number of Shares
Unvested at December 31, 2017		1,164,040
Granted		296,005
Vested		(332,586	)
Forfeited		(171,212	)
Unvested at June 30, 2018		956,247

Total stock-based compensation expense recognized for restricted stock awards was $3,935,000 and $6,932,000 for the three and six months ended June 30, 2018, respectively, and $6,071,000 and $11,710,000 for the three and six months ended June 30, 2017, respectively.

Stock Options

A summary of stock option activity under the 2010 Stock Plan and the 2013 Stock Plan for the six months ended June 30, 2018 is as follows:

	Number of Shares			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term (In Years)		Aggregate Intrinsic Value
								(in thousands)
Outstanding as of December 31, 2017		666,717		$	19.53		5.6	$	32,450
Granted		—			—
Exercised		(272,917	)		19.48
Forfeited		(7,826	)		34.10
Outstanding as of June 30, 2018		385,974		$	19.27		5.3	$	45,325
Exercisable as of June 30, 2018		360,495		$	18.40		5.1	$	42,646

The Company recorded total stock-based compensation expense for stock options granted to employees, directors and non-employees from the 2010 Stock Plan and the 2013 Stock Plan of $150,000 and $361,000 for the three and six months ended June 30, 2018, respectively, and $655,000 and $1,415,000 for the three and six months ended June 30, 2017, respectively.

The Company recorded stock-based compensation expense in the statements of operations and comprehensive loss as follows (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2018		2017		2018		2017
Cost of revenue	$	309	$	563	$	547	$	1,658
Selling and marketing		957		1,297		1,869		2,517
General and administrative		1,813		3,159		3,094		5,937
Research and development		1,006		1,707		1,783		3,013
Total	$	4,085	$	6,726	$	7,293	$	13,125

As of June 30, 2018, unrecognized compensation cost of approximately $36,046,000 related to non-vested stock options and restricted stock awards is expected to be recognized over weighted-average period of 2.4 years.